Pfizer (NYSE:PFE) Price Target Raised to $28.00

Pfizer (NYSE:PFE) had its target price boosted by Royal Bank Of Canada from $25.00 to $28.00 in a research report released on Wednesday morning,Benzinga reports. Royal Bank Of Canada currently has a sector perform rating on the biopharmaceutical company’s stock.

PFE has been the subject of several other reports. BMO Capital Markets decreased their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. Cantor Fitzgerald boosted their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. HSBC upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. Scotiabank raised their price target on shares of Pfizer from $30.00 to $33.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Finally, Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Six investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $30.39.

Pfizer Stock Down 1.7%

NYSE:PFE traded down $0.50 during mid-day trading on Wednesday, hitting $29.38. 48,291,518 shares of the company’s stock traded hands, compared to its average volume of 30,697,644. The company has a fifty day moving average of $28.74 and a 200 day moving average of $26.90. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer has a twelve month low of $23.62 and a twelve month high of $31.44. The company has a market capitalization of $167.46 billion, a P/E ratio of 41.97, a P/E/G ratio of 2.08 and a beta of 0.31.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.13. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business had revenue of $16.58 billion during the quarter, compared to the consensus estimate of $15.85 billion. During the same quarter last year, the company earned $0.87 earnings per share. The company’s quarterly revenue was down .4% on a year-over-year basis. On average, analysts forecast that Pfizer will post 3.03 EPS for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 5.9%. The ex-dividend date is Friday, November 6th. Pfizer’s dividend payout ratio (DPR) is presently 245.71%.

Institutional Investors Weigh In On Pfizer

Institutional investors and hedge funds have recently modified their holdings of the company. TOWER TRUST & INVESTMENT Co raised its position in Pfizer by 1.9% during the 3rd quarter. TOWER TRUST & INVESTMENT Co now owns 19,322 shares of the biopharmaceutical company’s stock worth $551,000 after buying an additional 357 shares during the last quarter. Angeles Wealth Management LLC lifted its stake in Pfizer by 2.2% during the 2nd quarter. Angeles Wealth Management LLC now owns 17,009 shares of the biopharmaceutical company’s stock valued at $410,000 after acquiring an additional 358 shares during the period. Manchester Financial Inc. boosted its holdings in shares of Pfizer by 2.9% in the 2nd quarter. Manchester Financial Inc. now owns 13,168 shares of the biopharmaceutical company’s stock valued at $317,000 after acquiring an additional 365 shares during the last quarter. Signature Equity Partners LLC boosted its holdings in shares of Pfizer by 22.9% in the 3rd quarter. Signature Equity Partners LLC now owns 2,067 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 385 shares during the last quarter. Finally, Delta Financial Advisors LLC boosted its holdings in shares of Pfizer by 1.6% in the 1st quarter. Delta Financial Advisors LLC now owns 25,266 shares of the biopharmaceutical company’s stock valued at $709,000 after acquiring an additional 398 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer’s third-quarter results beat analyst expectations, and the company raised its 2026 earnings outlook. Reports also highlighted momentum from newer products, although margin pressure remains a concern. Pfizer Q3 Earnings Rebuild Confidence As New Drugs Gain Ground
• Positive Sentiment: Guggenheim reiterated a Buy view and raised its price target to $33 from $31, signaling potential upside in the analyst’s view. Pfizer Receives a Buy from Guggenheim
• Neutral Sentiment: Pfizer updated an ulcerative-colitis treatment-pattern study and advanced a Phase 3 RSV-vaccine study in high-risk children. The announcements describe ongoing research; no efficacy or safety results were provided in the summaries. Pfizer Advances Phase 3 RSV Vaccine Study
• Negative Sentiment: DZ Bank cut its rating on Pfizer from Buy to Hold, a less favorable view that may temper optimism from other analysts. Pfizer also lagged in a news report focused on Moderna’s earnings-driven gain, though that comparison is not a change in Pfizer’s fundamentals. DZ Bank recommendations Moderna Climbs as Pfizer Dips

About Pfizer